CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Modern Immunotherapy for Triple-Negative Breast Cancer

Modern Immunotherapy for...

Recent Developments in Cancer Immunotherapy

Recent Developments in Cancer...

Novel Immunotherapies To Redefine The Cancer Therapy Market

Novel Immunotherapies To Redefine The...

 Types of Cancers that Immunotherapy May Help Cure

Types of Cancers that Immunotherapy...

Multiomic Preclinical Models to Define the Mechanism of Action

Multiomic Preclinical Models to...

Developing Patient-Centric Precision Oncology Therapies: Begin With The End In Mind

Developing Patient-Centric Precision...

What the New EMA Draft

What the New EMA Draft "Guideline on...

Pharmaceutical Tablet Coating - Past, Present and Future

Pharmaceutical Tablet Coating - Past,...

Modern Immunotherapy for Triple-Negative Breast Cancer

Modern Immunotherapy for...

Recent Developments in Cancer Immunotherapy

Recent Developments in Cancer...

Novel Immunotherapies To Redefine The Cancer Therapy Market

Novel Immunotherapies To Redefine The...

 Types of Cancers that Immunotherapy May Help Cure

Types of Cancers that Immunotherapy...

Multiomic Preclinical Models to Define the Mechanism of Action

Multiomic Preclinical Models to...

Developing Patient-Centric Precision Oncology Therapies: Begin With The End In Mind

Developing Patient-Centric Precision...

What the New EMA Draft

What the New EMA Draft "Guideline on...

Pharmaceutical Tablet Coating - Past, Present and Future

Pharmaceutical Tablet Coating - Past,...

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Life Sciences Review | Tuesday, May 17, 2022
Tweet

Reduced risk of cancer deaths due to the addition of immunotherapy drug nivolumab to chemotherapy for patients with non-small cell lung cancer (NSCLC). This addition has resulted in zero active cancer cells after the removal of the tumour in patients who received chemotherapy alone.


FREMONT, CA: The Federal Drug Administration (FDA) has approved the first immunotherapy/chemotherapy combination treatment for patients with operable NSCLC. This approval comes from the study led by the researchers at the Johns Hopkins Kimmel Cancer Centre and the Bloomberg Kimmel Institute for Cancer Immunotherapy.


Patrick Forde, principal investigator of the trial, co-director of the upper aerodigestive cancer division at the Johns Hopkins Kimmel Cancer Centre, and associate professor of oncology, says that in this trial they found the addition of nivolumab to standard neoadjuvant chemotherapy reduced the risk of recurrence of cancer or death by more than one third. The treatment, he says, was also associated with mostly improved outcomes of surgery, including less extensive surgery, less blood loss, and shorter time in the operating system.


Forde says that the standard treatment for resectable lung cancer to remove the tumour is surgery, but most patients experience lung cancer recurrence after surgery, and it’s mostly incurable. He goes on to say that when drugs like cisplatin or carboplatin are given either before or after surgery, patient survival improves by only five percent after 5 years. 358 patients with stage 1B to 3A resectable NSCLC were randomly assigned to receive platinum-doublet chemotherapy for three cycles, with or without 360 milligrams of the anti-PD-1 immunotherapy drug nivolumab, followed by surgery. Those who received combination therapy had a pathological complete response rate of 24 percent, compared to 2.2 percent for those who only received chemotherapy. The combination recipients also had better surgical outcomes and a 37 percent lower risk of cancer recurrence or death.


In an earlier study, lung cancer patients with operable tumours were given two doses of nivolumab for four weeks before surgery. Out of them, nine of the patients had a 90 percent or more reduction in the number of live cancer cells in the tumour.


Immunotherapy Plus Chemotherapy Before Surgery Improves Outcomes for Patients with Lung Cancer – India Education | Latest Education News | Global Educational News | Recent Educational News (indiaeducationdiary.in)


Weekly Brief

loading
Top 10 Cancer Immunotherapy Solutions Companies – 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Antibodies: Immunoglobulin Isotypes

Life Science Consulting Services Trends

Rani Therapeutics and Celltrion Partner to Develop Oral Monoclonal Antibodies

ProPhase Labs Acquires BE-Smart Esophageal Pre-Cancer Screening Test

The Influence of Pharmaceutical Distributors on U.S. Drug Expenditures

Tips to Improve Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/lung-cancer-patients-can-see-improved-results-with-immunotherapy-along-with-chemotherapy-before-surgery-nwid-800.html